These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325 [TBL] [Abstract][Full Text] [Related]
11. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673 [TBL] [Abstract][Full Text] [Related]
12. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test]. Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264 [TBL] [Abstract][Full Text] [Related]
13. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia. Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317 [TBL] [Abstract][Full Text] [Related]
15. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. Kung HF; Alavi A; Chang W; Kung MP; Keyes JW; Velchik MG; Billings J; Pan S; Noto R; Rausch J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408 [TBL] [Abstract][Full Text] [Related]
16. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Schwarz J; Tatsch K; Arnold G; Ott M; Trenkwalder C; Kirsch CM; Oertel WH Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906 [TBL] [Abstract][Full Text] [Related]
17. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354 [TBL] [Abstract][Full Text] [Related]
18. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients]. Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843 [TBL] [Abstract][Full Text] [Related]
19. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation--preliminary results. Ebert D; Feistel H; Kaschka W; Barocka A; Pirner A Biol Psychiatry; 1994 Jun; 35(11):880-5. PubMed ID: 8054411 [TBL] [Abstract][Full Text] [Related]
20. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Hertel A; Weppner M; Baas H; Schreiner M; Maul FD; Baum RP; Fischer PA; Hör G Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]